Figure 10
LX2343 attenuated tau pathology in ICV-STZ rats. (A) P396-tau in the brain of ICV-STZ rats was determined using immunohistochemistry, scale bar: 100 μm. (B) Statistical analysis of A (one-way ANOVA, Dunnett's multiple comparison test, **P<0.01 versus SV. ##P<0.01 versus V). (C–F) Western blot and quantification results demonstrated that LX2343 reduced phosphorylation of tau in cortical and hippocampal homogenates of ICV-STZ rats (one-way ANOVA, Dunnett's multiple comparison test: *P<0.05, **P<0.01 versus SV. #P<0.05, ##P<0.01 versus V). (G–J) Western blot and quantification demonstrated that LX2343 reduced the activity of GSK-3β in cortical and hippocampal homogenates of ICV-STZ rats (one-way ANOVA, Dunnett's multiple comparison test: *P<0.05, **P<0.01 versus SV. #P<0.05, ##P<0.01 versus V). V: Rats treated with vehicle, SV: Rats ICV injected with STZ and treated with vehicle, SL: Rats injected with STZ and treated with 7 mg·kg−1·d−1 LX2343, SH: Rats injected with STZ and treated with 21 mg·kg−1·d−1 LX2343. All values were presented as the mean±SEM (n=10 per group). GAPDH was used as the loading control in Western blot assays. Data were obtained from three independent experiments.
